Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Authors
Mohammad Reza Zali1,*, Hamid Mohaghegh Shalmani2, Mohsen Norouzinia2, Amir Hooshang MohammadAlizadeh2, Azita Nowroozi2, Negar Behrouz2
1Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), zali@ams.ac.ir, Tehran, IR.Iran
2Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, IR.Iran
*Corresponding Author: Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), zali@ams.ac.ir, Tehran, IR.Iran. Email: zali@ams.ac.ir
How to Cite:Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
Abstract
Background and Aim: Pegylation of interferon alfa-2a is a new modality for treatment of chronic hepatitis C. This clinical trial was conducted to evaluate the efficacy and safety of PEG IFN in combination with ribavirin in CHC patients.
Methods: Fifty seven patients with HCV RNA in serum, persistently elevated ALT and chronic C hepatitis on liver biopsy enrolled to this study. The patients received PEG IFN 180 micg per week plus ribavirin 10-15 mg/kg per day.
Results: HCV RNA was negative in 37 patients (74%) after three months of beginning of study (EVR) and SVR occurred in 50% of all patients.
Conclusion: Peginterferon alfa-2a plus ribavirin is safe and effective in treatment of naïve patients and relapsers.
Highlights
Copyright
© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Sep
2004
The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial
Nasser Ebrahimi Daryani,
Babak Haghpanah,
Ali Reza Sayyah,
Ali Asad Hashtroudi,
Mohammad Bashashati,
Parisa Poursamimi
,et al.Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
30
Sep
2004
Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian
Seyed Moayed Alavian,
Behzad Hajarizadeh,
Bashir Hajibeigi,
Taher Doroudi,
Amir Kambiz Hamadanizadeh,
Koroush Abar
Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:
1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari
Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955
1
Jan
2006
Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study
SM Alavian,
A Kabir,
B Hajarizadeh,
M Nayebpour,
T Dorodi,
FE Baralle
Alavian S, Kabir A, Hajarizadeh B, Nayebpour M, Dorodi T, et al. Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study. Shiraz E-Med J. 2006;7(1):20390. doi:
14
Dec
2013
Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
Zaigham Abbas,
Ghiasun Nabi Tayyab,
Mustafa Qureshi,
Mohammad Sadik Memon,
Amna Subhan,
Tanzila Shakir
,et al.Abbas Z, Tayyab GN, Qureshi M, Memon MS, Subhan A, et al. Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin. Hepat Mon. 2013;13(12):e14146. doi: https://doi.org/10.5812/hepatmon.14146
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 2
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 5 hours ago
- OpenAlex: 0
Last Update: 6 hours ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0